Achieve Life Sciences, Inc.
ACHVAchieve Life Sciences, Inc. in brief
Achieve Life Sciences, Inc. is a listed company in the Biotechnology industry, based in Seattle, Washington, USA. Its market value was $791 M on 30 October 2026, which makes it the 10,435th largest listed company in the world and the 2,207th largest in the USA on this site. It employs about 28 people and Andrew D. Goldberg is its chief executive. Its shares trade under the symbol ACHV (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Achieve Life Sciences, Inc.
We are a late-stage clinical specialty pharmaceutical company with the sole mission to address the global nicotine dependence epidemic through the development and commercialization of cytisinicline. There are an estimated 29 million adults in the United States alone who smoke combustible cigarettes and an estimated 17 million adults in the United States who utilize e-cigarettes. Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke. Our primary focus is to address this global epidemic.
From the company's annual report filed with the US SEC: read the report
Achieve Life Sciences, Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2008
- ✎Renamed Oncogenex Pharmaceuticals, Inc.Formerly Sonus Pharmaceuticals Inc.
- 2017
- ✎Renamed Achieve Life Sciences, Inc.Formerly Oncogenex Pharmaceuticals, Inc..
Events of Achieve Life Sciences, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,616 (Jan 2022) · #4,864 (Dec 2022) · #4,067 (Jul 2023) · #3,784 (Jan 2024) · #1,649 (Mar 2026) · #2,249 (Aug 2026) · #2,243 (Oct 2026) · #2,208 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 36.8×
- Free cash flow yield
- -6.3%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -253.9%
- Liabilities / assets
- 48.5%
- Profit per employee
- $-2.0 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | — | $-55M | — |
| Dec 2024 | — | — | — | $-40M | — |
| Dec 2023 | — | — | — | $-30M | — |
| Dec 2022 | — | — | — | $-42M | — |
| Dec 2021 | — | — | — | $-33M | — |
| Dec 2020 | — | — | — | $-15M | — |
| Dec 2019 | — | — | — | $-16M | — |
| Dec 2018 | — | — | — | $-13M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-49M | $0M | $-49M | $-1.25 | — |
| Dec 2024 | $-30M | — | — | $-1.24 | — |
| Dec 2023 | $-24M | $0M | $-25M | $-1.50 | — |
| Dec 2022 | $-38M | — | — | $-4.00 | — |
| Dec 2021 | $-29M | — | — | $-4.08 | — |
| Dec 2020 | $-13M | $0M | $-13M | $-5.42 | — |
| Dec 2019 | $-15M | $0M | $-15M | $-39.76 | — |
| Dec 2018 | $-11M | $0M | $-11M | $-72.29 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 1, 20268-KCurrent reportDirectors or officers changed
- Aug 14, 20268-KCurrent reportOther events
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 6, 20268-KCurrent reportBylaws amended · Shareholder vote
- Jun 8, 2026DEF 14AProxy statement
- Jun 2, 20268-KCurrent reportDirectors or officers changed
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations · Directors or officers changed
- Apr 30, 202610-K/AAnnual report (amended) · period to Dec 2025
Official filings of Achieve Life Sciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- —
- Net income
- $-55 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $42 M
- Total liabilities
- $20 M
- Total equity
- $22 M
As of December-2025
Top 100 institutional investors in Achieve Life Sciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 7,614,836 | 0 (0.00%) | 6.92% | $62 M | Nov 16, 2026 |
| 2 | TPG GP A, LLC | 6,877,580 | 0 (0.00%) | 6.25% | $56 M | Nov 16, 2026 |
| 3 | venBio Partners LLC | 5,914,720 | 0 (0.00%) | 5.38% | $48 M | Nov 16, 2026 |
| 4 | Venrock Adviser, LLC | 5,502,064 | +2,751,032 (+100.00%) | 5.00% | $45 M | Nov 16, 2026 |
| 5 | BlackRock, Inc. | 5,487,278 | +215,261 (+4.08%) | 4.99% | $44 M | Nov 13, 2026 |
| 6 | Paradigm Biocapital Advisors LP | 4,951,856 | 0 (0.00%) | 4.50% | $40 M | Nov 16, 2026 |
| 7 | Propel Bio Management, LLC | 3,864,148 | -169,870 (-4.21%) | 3.51% | $31 M | Nov 13, 2026 |
| 8 | Jpmorgan Chase & Co | 3,788,388 | +3,756,099 (+11632.75%) | 3.44% | $31 M | Nov 12, 2026 |
| 9 | Marshall Wace, LLP | 3,770,313 | 0 (0.00%) | 3.43% | $31 M | Nov 13, 2026 |
| 10 | State Street Corp | 3,718,240 | +772,714 (+26.23%) | 3.38% | $30 M | Nov 12, 2026 |
| 11 | Eventide Asset Management, LLC | 3,571,721 | +1,351,721 (+60.89%) | 3.25% | $29 M | Nov 13, 2026 |
| 12 | Vanguard Capital Management LLC | 3,480,234 | -660,578 (-15.95%) | 3.16% | $28 M | Nov 13, 2026 |
| 13 | Logos Global Management LP | 3,200,000 | -2,225,000 (-41.01%) | 2.91% | $26 M | Nov 16, 2026 |
| 14 | Franklin Templeton Inc | 3,130,950 | -1,822,270 (-36.79%) | 2.85% | $25 M | Nov 12, 2026 |
| 15 | Janus Henderson Group Ltd. | 2,751,032 | — | 2.50% | $22 M | Nov 16, 2026 |
| 16 | Vivo Capital, LLC | 2,751,032 | 0 (0.00%) | 2.50% | $22 M | Nov 13, 2026 |
| 17 | Orbimed Advisors LLC | 2,344,200 | New | 2.13% | $19 M | Nov 16, 2026 |
| 18 | Geode Capital Management, LLC | 2,156,709 | +93,988 (+4.56%) | 1.96% | $17 M | Nov 6, 2026 |
| 19 | Boxer Capital Management, LLC | 2,150,000 | New | 1.95% | $17 M | Nov 16, 2026 |
| 20 | Wellington Management Group LLP | 1,648,859 | +221,944 (+15.55%) | 1.50% | $13 M | Nov 16, 2026 |
| 21 | Alyeska Investment Group, L.P. | 975,722 | -950,000 (-49.33%) | 0.89% | $8 M | Nov 16, 2026 |
| 22 | LPL Financial LLC | 973,585 | +71,330 (+7.91%) | 0.88% | $8 M | Nov 6, 2026 |
| 23 | Simplify Asset Management Inc. | 932,105 | -500,000 (-34.91%) | 0.85% | $8 M | Oct 27, 2026 |
| 24 | Bank of New York Mellon Corp | 753,900 | +535,774 (+245.63%) | 0.69% | $6 M | Nov 5, 2026 |
| 25 | Northern Trust Corp | 743,368 | -392 (-0.05%) | 0.68% | $6 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Spruce Street Capital LP | 736,637 | 0 (0.00%) | 0.67% | $6 M | Nov 13, 2026 |
| 27 | Vanguard Portfolio Management LLC | 735,325 | +197,729 (+36.78%) | 0.67% | $6 M | Nov 13, 2026 |
| 28 | Ameriprise Financial Inc | 731,188 | New | 0.66% | $6 M | Nov 16, 2026 |
| 29 | Vanguard Fiduciary Trust Co | 620,907 | +27,156 (+4.57%) | 0.56% | $5 M | Nov 13, 2026 |
| 30 | Raymond James Financial Inc | 583,491 | +37,173 (+6.80%) | 0.53% | $5 M | Nov 12, 2026 |
| 31 | Mercer Global Advisors Inc /adv | 550,551 | New | 0.50% | $4 M | Nov 16, 2026 |
| 32 | ADAR1 Capital Management, LLC | 508,199 | +454,399 (+844.61%) | 0.46% | $4 M | Nov 16, 2026 |
| 33 | KVP Capital Advisors, LP | 462,355 | 0 (0.00%) | 0.42% | $4 M | Nov 16, 2026 |
| 34 | Adage Capital Partners GP, L.L.C. | 460,000 | New | 0.42% | $4 M | Nov 16, 2026 |
| 35 | Caption Management, LLC | 429,294 | +201,561 (+88.51%) | 0.39% | $3 M | Nov 16, 2026 |
| 36 | Blue Owl Capital Holdings LP | 412,654 | New | 0.38% | $3 M | Nov 13, 2026 |
| 37 | Point72 Asset Management, L.P. | 376,704 | New | 0.34% | $3 M | Nov 16, 2026 |
| 38 | FMR LLC | 338,850 | +321,143 (+1813.65%) | 0.31% | $3 M | Nov 10, 2026 |
| 39 | Renaissance Technologies LLC | 317,183 | +139,134 (+78.14%) | 0.29% | $3 M | Nov 12, 2026 |
| 40 | UBS Group AG | 292,583 | -20,421 (-6.52%) | 0.27% | $2 M | Nov 10, 2026 |
| 41 | Citadel Advisors LLC | 274,826 | +151,697 (+123.20%) | 0.25% | $2 M | Nov 16, 2026 |
| 42 | Invesco Ltd. | 235,387 | +193,095 (+456.58%) | 0.21% | $2 M | Nov 12, 2026 |
| 43 | Charles Schwab Investment Management Inc | 232,138 | 0 (0.00%) | 0.21% | $2 M | Nov 16, 2026 |
| 44 | Bank Of America Corp /de/ | 212,754 | +27,679 (+14.96%) | 0.19% | $2 M | Nov 16, 2026 |
| 45 | Morgan Stanley | 207,716 | +148,342 (+249.84%) | 0.19% | $2 M | Nov 13, 2026 |
| 46 | Nuveen, LLC | 182,510 | -8,640 (-4.52%) | 0.17% | $1 M | Nov 10, 2026 |
| 47 | Silverarc Capital Management, LLC | 158,950 | -68,228 (-30.03%) | 0.14% | $1 M | Nov 12, 2026 |
| 48 | Goldman Sachs Group Inc | 155,598 | +114,622 (+279.73%) | 0.14% | $1 M | Nov 16, 2026 |
| 49 | Informed Momentum Co LLC | 147,269 | New | 0.13% | $1 M | Nov 16, 2026 |
| 50 | Hurricane Capital Advisors LLC | 137,550 | +102,550 (+293.00%) | 0.13% | $1 M | Nov 16, 2026 |
| 51 | Cantor Fitzgerald, L. P. | 121,876 | -121,386 (-49.90%) | 0.11% | $1 M | Nov 16, 2026 |
| 52 | Greenland Capital Management LP | 120,000 | New | 0.11% | $1 M | Nov 16, 2026 |
| 53 | Wells Fargo & Company/mn | 119,232 | -51,401 (-30.12%) | 0.11% | $1 M | Nov 16, 2026 |
| 54 | SEI Investments Co | 109,350 | +88,850 (+433.41%) | 0.10% | $1 M | Nov 10, 2026 |
| 55 | Squarepoint Ops LLC | 102,572 | New | 0.09% | $1 M | Nov 9, 2026 |
| 56 | Rafferty Asset Management, LLC | 90,967 | +53,446 (+142.44%) | 0.08% | $1 M | Nov 13, 2026 |
| 57 | Rhumbline Advisers | 89,921 | +2,898 (+3.33%) | 0.08% | $1 M | Nov 10, 2026 |
| 58 | Blue Trust, Inc. | 85,888 | 0 (0.00%) | 0.08% | $1 M | Oct 15, 2026 |
| 59 | Two Sigma Investments, LP | 81,648 | -359,539 (-81.49%) | 0.07% | $1 M | Nov 16, 2026 |
| 60 | Engineers Gate Manager LP | 79,004 | New | 0.07% | $1 M | Nov 16, 2026 |
| 61 | Polen Capital Management LLC | 78,146 | New | 0.07% | $1 M | Nov 13, 2026 |
| 62 | Prospera Financial Services Inc | 74,550 | New | 0.07% | $1 M | Nov 4, 2026 |
| 63 | Shay Capital LLC | 71,853 | -20,957 (-22.58%) | 0.07% | $1 M | Nov 16, 2026 |
| 64 | Deutsche Bank AG\ | 67,558 | -9,927 (-12.81%) | 0.06% | $1 M | Nov 6, 2026 |
| 65 | Manchester Financial Inc | 67,177 | 0 (0.00%) | 0.06% | $1 M | Oct 15, 2026 |
| 66 | Members Wealth LLC | 66,763 | 0 (0.00%) | 0.06% | $1 M | Oct 20, 2026 |
| 67 | Price T Rowe Associates Inc /MD/ | 64,769 | 0 (0.00%) | 0.06% | $1 M | Nov 16, 2026 |
| 68 | WINTON GROUP Ltd | 58,800 | +16,300 (+38.35%) | 0.05% | $0 M | Nov 12, 2026 |
| 69 | Virtus Investment Advisers, LLC | 57,488 | -1,787 (-3.01%) | 0.05% | $0 M | Nov 12, 2026 |
| 70 | Vanguard Global Advisers, LLC | 56,745 | +24,337 (+75.10%) | 0.05% | $0 M | Nov 13, 2026 |
| 71 | Boothbay Fund Management, LLC | 54,807 | New | 0.05% | $0 M | Nov 16, 2026 |
| 72 | Bank Of Nova Scotia | 49,419 | New | 0.04% | $0 M | Nov 13, 2026 |
| 73 | BNP Paribas Financial Markets | 46,679 | -74,536 (-61.49%) | 0.04% | $0 M | Nov 12, 2026 |
| 74 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 45,002 | +4,952 (+12.36%) | 0.04% | $0 M | Nov 16, 2026 |
| 75 | Alliancebernstein L.P. | 44,920 | -4,020 (-8.21%) | 0.04% | $0 M | Nov 16, 2026 |
| 76 | Osaic Holdings, Inc. | 44,426 | +1,311 (+3.04%) | 0.04% | $0 M | Nov 12, 2026 |
| 77 | XTX Topco Ltd | 42,612 | -47,418 (-52.67%) | 0.04% | $0 M | Nov 16, 2026 |
| 78 | Citigroup Inc | 40,578 | -33,536 (-45.25%) | 0.04% | $0 M | Nov 4, 2026 |
| 79 | MetLife Investment Management, LLC | 39,509 | -6,476 (-14.08%) | 0.04% | $0 M | Nov 16, 2026 |
| 80 | Quadrature Capital Ltd | 36,794 | New | 0.03% | $0 M | Nov 13, 2026 |
| 81 | Barclays PLC | 36,217 | +16,223 (+81.14%) | 0.03% | $0 M | Nov 6, 2026 |
| 82 | Susquehanna International Group, LLP | 35,095 | +4,723 (+15.55%) | 0.03% | $0 M | Nov 16, 2026 |
| 83 | Profund Advisors LLC | 32,353 | +12,497 (+62.94%) | 0.03% | $0 M | Oct 29, 2026 |
| 84 | Ameriflex Group, Inc. | 32,063 | -1,535 (-4.57%) | 0.03% | $0 M | Nov 16, 2026 |
| 85 | Rockefeller Capital Management L.P. | 30,000 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 86 | BCV Asset Management Inc. | 26,315 | -50 (-0.19%) | 0.02% | $0 M | Nov 6, 2026 |
| 87 | Robertson Stephens Wealth Management, LLC | 25,000 | 0 (0.00%) | 0.02% | $0 M | Oct 16, 2026 |
| 88 | Keating Financial Advisory Services, Inc. | 24,911 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 89 | Magnetar Financial LLC | 23,818 | New | 0.02% | $0 M | Nov 13, 2026 |
| 90 | Police & Firemen's Retirement System of New Jersey | 22,958 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 91 | Manufacturers Life Insurance Company, The | 20,998 | +388 (+1.88%) | 0.02% | $0 M | Nov 13, 2026 |
| 92 | New York State Common Retirement Fund | 19,200 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 93 | Persistent Asset Partners Ltd | 17,826 | +15,046 (+541.22%) | 0.02% | $0 M | Nov 13, 2026 |
| 94 | Foundations Investment Advisors, LLC | 15,554 | New | 0.01% | $0 M | Nov 12, 2026 |
| 95 | Creative Planning | 15,319 | New | 0.01% | $0 M | Nov 2, 2026 |
| 96 | SBI Securities Co., Ltd. | 14,965 | +124 (+0.84%) | 0.01% | $0 M | Oct 22, 2026 |
| 97 | Voya Investment Management LLC | 14,844 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 98 | Magnolia Capital Advisors LLC | 14,100 | -1,000 (-6.62%) | 0.01% | $0 M | Nov 16, 2026 |
| 99 | Royal Bank Of Canada | 14,010 | +1,634 (+13.20%) | 0.01% | $0 M | Nov 16, 2026 |
| 100 | Prudential Financial Inc | 13,450 | +410 (+3.14%) | 0.01% | $0 M | Nov 16, 2026 |
Superinvestors holding Achieve Life Sciences, Inc.
1 of the well-known investors value.today follows, from their newest Form 13F.
- Polen Capital · Polen Capital's team$1 Mnew · Sep 30, 2026
Mutual funds holding Achieve Life Sciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 3.11 M | $20 M | 2.8% | <0.01% | +99% | Jun 30, 2026 |
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 2.22 M | $14 M | 2.0% | 0.81% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.99 M | $13 M | 1.8% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 1.35 M | $9 M | 1.2% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 1.10 M | $7 M | 1.00% | 0.61% | −30% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 957,389 | $6 M | 0.87% | <0.01% | +64% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 851,832 | $5 M | 0.77% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 731,016 | $5 M | 0.66% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 706,649 | $5 M | 0.64% | 0.39% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 261,589 | $2 M | 0.24% | 0.11% | +117% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 276,242 | $1 M | 0.25% | <0.01% | −1.5% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 189,138 | $1 M | 0.17% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 145,507 | $1 M | 0.13% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 103,456 | $1 M | 0.09% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 84,148 | $1 M | 0.08% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 97,174 | $1 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 72,934 | $0 M | 0.07% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 67,194 | $0 M | 0.06% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 80,161 | $0 M | 0.07% | <0.01% | +5.1% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 56,300 | $0 M | 0.05% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 46,642 | $0 M | 0.04% | <0.01% | +71% | Jul 31, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 45,865 | $0 M | 0.04% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 43,000 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 42,235 | $0 M | 0.04% | <0.01% | +58% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 40,160 | $0 M | 0.04% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 37,028 | $0 M | 0.03% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 33,105 | $0 M | 0.03% | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 37,770 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 30,577 | $0 M | 0.03% | <0.01% | +66% | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 28,131 | $0 M | 0.03% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 26,074 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 25,500 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 24,203 | $0 M | 0.02% | 0.04% | −4.5% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 22,114 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 19,040 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 19,040 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 17,463 | $0 M | 0.02% | 0.05% | +104% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 17,167 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 16,088 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 13,627 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 12,486 | $0 M | 0.01% | 0.02% | +54% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 12,219 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 11,873 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 11,732 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 10,451 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 9,509 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 9,115 | $0 M | <0.01% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 8,529 | $0 M | <0.01% | <0.01% | +60% | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 7,071 | $0 M | <0.01% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 7,064 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 6,847 | $0 M | <0.01% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 6,715 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 6,224 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 5,335 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 3,846 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 3,491 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,706 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 2,633 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust | 2,870 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,965 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,304 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 976 | $0 M | <0.01% | <0.01% | −3.1% | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 725 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 63 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Achieve Life Sciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Richard Alistair StewartDirector | Sell | -20,626 | $8.490 | $175 K | 208,249 | Form 4 |
| filed | Mark K. OkiChief Financial Officer | Option exercise | +168,000 | — | — | 178,000 | Form 4 |
| filed | Richard Alistair StewartChief Executive Officer, Director | Option exercise | +297,500 | — | — | 358,376 | Form 4 |
| filed | Mark K. OkiChief Financial Officer | Sell | -50,060 | $2.920 | $146 K | 127,940 | Form 4 |
| filed | Richard Alistair StewartChief Executive Officer, Director | Sell | -129,501 | $2.920 | $378 K | 228,875 | Form 4 |
| filed | Jerry WanPrincipal Accounting Officer | Option exercise | +34,100 | — | — | 46,764 | Form 4 |
| filed | Jaime XinosChief Commercial Officer | Option exercise | +69,000 | — | — | 95,286 | Form 4 |
| filed | Thomas Braxton KingDirector | Option exercise | +455,000 | — | — | 455,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Achieve Life Sciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split ; 1-for-10 reverse split
Fails to deliver
- : 147,962 shares at $7.19
- : 45,489 shares at $6.85
- : 155 shares at $6.49
- : 134 shares at $6.50
- : 145 shares at $6.51
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Achieve Life Sciences, Inc. scorecard#
Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median36.8×Price to book 36.8× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-6.2%Free cash flow is -6.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.25 vs -1.24Diluted EPS -1.25 in fiscal 2025 against -1.24 the year before (report's currency).
- ✗Net income higher than five years earlier-$55 M-$55 M in fiscal 2025 against -$15 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$55 MNet income -$55 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-257.7%-257.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.4×Current ratio 4.39 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year35.9%Diluted shares up 35.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Achieve Life Sciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | — | — | — | 0—— | 0—— | — | — | |
| Research and development | — | 23+44.3%— | 16−47.4%— | 30+25.5%— | 24+248%— | 6.9−28.9%— | 9.7+64.9%— | 5.9+89.2%— | 3.1+984%— | 0.3r15—— | |
| General and administrative | — | 16+42.1%— | 11+6.7%— | 11+17.5%— | 9.1+16.0%— | 7.9+14.8%— | 6.9−1.3%— | 6.9+96.7%— | 3.5+147%— | 1.4r8.9—— | |
| Total costs and expenses | 55+40.5%— | 39+43.4%— | 27−33.2%— | 41+23.3%— | 33+124%— | 15−10.8%— | 17+29.0%— | 13+93.2%— | 6.6+287%— | 1.7r26—— | |
| Interest and finance income | 1.5−36.5%— | 2.4+186%— | 0.8+315%— | 0.2+1071%— | 0.0−75.4%— | 0.1−59.4%— | 0.2−0.6%— | 0.2+714%— | 0.0−89.7%— | 0.2—— | |
| Interest expense and finance costs | 0.8−62.4%— | 2.2−23.6%— | 2.9+59.5%— | 1.8—— | — | — | — | — | — | — | |
| Other non-operating income (expense) | 0.2—— | −0.8—— | −2.6—— | −1.6—— | −0.1−390%— | 0.0−85.0%— | 0.1+5.6%— | 0.1—— | −7.0—— | −0.0r1.1—— | |
| Income before tax | −55—— | −40—— | −30—— | −42—— | −33—— | −15—— | −16—— | −13—— | −14—— | −1.7—— | |
| Income tax | — | — | — | — | — | — | — | — | — | 0—— | |
| Net income including minority interests | −55—— | −40—— | −30—— | −42—— | −33—— | −15—— | −16—— | −13—— | −11—— | −1.2—— | |
| Net income attributable to shareholders | −55—— | −40—— | −30—— | −42—— | −33—— | −15—— | −16—— | −13—— | −11—— | −1.2r−20—— | |
| Earnings per share, basic | -1.25—— | -1.24—— | -1.50—— | -4.00—— | -4.08—— | -5.42—— | -39.76r-1.99—— | -72.29r-3.61—— | -22.07r-2.21—— | -581.25r-0.67—— | |
| Earnings per share, diluted | -1.25—— | -1.24—— | -1.50—— | -4.00—— | -4.08—— | -5.42—— | -39.76r-1.99—— | -72.29r-3.61—— | -22.07r-2.21—— | -581.25r-0.67—— | |
| Shares, weighted average (basic) | 44+35.9%— | 32+61.8%— | 20r20+87.2%— | 11+30.5%— | 8.1+199%— | 2.7—— | — | — | — | — | |
| Shares, weighted average (diluted) | 44+35.9%— | 32+61.8%— | 20r20+87.2%— | 11+30.5%— | 8.1+199%— | 2.7+559%— | 0.4r8.2+135%— | 0.2r3.5−63.4%— | 0.5r4.8+22483%— | 0.0r30—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 21+64.1%50.1% | 13−18.0%33.0% | 16−37.2%80.3% | 25−42.4%82.6% | 43+20.0%90.5% | 36+115%89.0% | 17+75.1%79.1% | 9.5+80.1%49.9% | 5.3+35127%53.4% | 0.0r15—0.4% | |
| Short-term investments | 15−28.4%37.0% | 22—55.9% | — | — | — | — | — | 5.1—26.7% | — | 10—269% | |
| Receivables | — | — | — | — | — | — | 0.0+14.3%0.0% | 0.0−22.2%0.0% | 0.0−98.1%0.1% | 0.5—12.6% | |
| Other current assets | — | 2.1+59.0%5.5% | 1.3−46.0%6.8% | 2.5+72.9%8.2% | 1.4+26.5%3.0% | 1.1+67.5%2.8% | 0.7r0.7−28.2%3.2% | 0.9—4.9% | — | 1.0—25.1% | |
| Current assets | 40+9.4%95.5% | 36+115%94.4% | 17−37.9%87.7% | 27−38.7%91.2% | 45+20.6%93.9% | 37+113%91.8% | 17+11.6%82.2% | 16+163%81.4% | 5.9+32722%59.7% | 0.0r27—0.5% | |
| Property, plant and equipment | 0.0−62.5%0.0% | 0.0−38.5%0.0% | 0.0+225%0.1% | 0.0−73.3%0.0% | 0.0−64.3%0.0% | 0.0−26.3%0.1% | 0.1+62.9%0.3% | 0.0−40.7%0.2% | 0.1−77.1%0.6% | 0.3—6.8% | |
| Right-of-use (leased) assets | 0.1−46.2%0.2% | 0.1+80.3%0.3% | 0.1−46.3%0.3% | 0.1r0.1+92.2%0.4% | 0.1−56.2%0.1% | 0.1−55.6%0.4% | 0.3—1.6% | — | — | — | |
| Goodwill | 1.00.0%2.5% | 1.00.0%2.7% | 1.00.0%5.3% | 1.00.0%3.5% | 1.00.0%2.2% | 1.00.0%2.6% | 1.00.0%4.9% | 1.00.0%5.4% | 1.00.0%10.5% | 1.0—27.2% | |
| Other intangible assets | 0.8−22.9%1.8% | 1.0−18.6%2.5% | 1.2−15.6%6.2% | 1.4−13.6%4.7% | 1.6−12.0%3.5% | 1.9−10.7%4.6% | 2.1−9.7%9.9% | 2.3−8.8%12.1% | 2.5−8.1%25.6% | 2.8—72.4% | |
| Total assets | 42+8.2%100% | 39+99.4%100% | 19−35.4%100% | 30−36.9%100% | 48+17.9%100% | 40+91.2%100% | 21+10.4%100% | 19+92.9%100% | 9.9+160%100% | 3.8r27—100% | |
| Accounts payable | — | 2.0+216%5.0% | 0.6−62.8%3.2% | 1.7+97.4%5.5% | 0.8+153%1.8% | 0.3−61.4%0.8% | 0.9+497%4.1% | 0.1−32.4%0.8% | 0.2+124%2.2% | 0.1r2.1—2.5% | |
| Current liabilities | 9.1+35.9%21.7% | 6.7−67.9%17.3% | 21−3.6%107% | 22+375%72.1% | 4.6+55.0%9.6% | 2.9+2.3%7.3% | 2.9−12.3%13.6% | 3.3+62.4%17.1% | 2.0−34.5%20.3% | 3.1r8.5—80.7% | |
| Lease liabilities (non-current) | 0.0−92.4%0.0% | 0.1+1000%0.2% | 0.0−91.3%0.0% | 0.1+1625%0.2% | 0.0−94.8%0.0% | 0.1−51.6%0.2% | 0.2+1225%0.8% | 0.0—0.1% | — | — | |
| Total liabilities | 20+14.3%48.5% | 18−14.8%45.9% | 21−3.9%107% | 22+11.3%72.3% | 19+547%41.0% | 3.0−0.5%7.5% | 3.0−7.7%14.4% | 3.3+63.0%17.2% | 2.0−37.0%20.3% | 3.2r8.5—84.0% | |
| Retained earnings | −260—−623% | −206—−532% | −166—−856% | −136—−454% | −94—−197% | −60—−150% | −46—−217% | −25—−133% | −13—−128% | −2.1r−197—−54.2% | |
| Shareholders' equity | 22+3.0%51.5% | 21—54.1% | −1.4−117%−7.5% | 8.3−70.4%27.7% | 28−24.8%59.0% | 37+107%92.5% | 18+14.2%85.6% | 16+101%82.8% | 7.9+1192%79.7% | 0.6r19—16.0% | |
| Total liabilities and equity | 42+8.2%100% | 39+99.4%100% | 19−35.4%100% | 30−36.9%100% | 48+17.9%100% | 40+91.2%100% | 21+10.4%100% | 19+92.9%100% | 9.9+160%100% | 3.8r27—100% | |
| Shares outstanding | 53+53.5%— | 35+63.9%— | 21+18.3%— | 18+89.3%— | 9.5+54.7%— | 6.1+315%— | 1.5r29−78.1%— | 6.7+463%— | 1.2r12+5528%— | 0.0r30—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2−0.4%— | 0.2+0.4%— | 0.2−3.4%— | 0.2−5.6%— | 0.3−2.0%— | 0.3—— | — | — | — | — | |
| Share-based compensation | 8.8+64.5%— | 5.3+54.8%— | 3.4+5.2%— | 3.3+49.5%— | 2.2+70.1%— | 1.3+7.1%— | 1.2+40.6%— | 0.9+145%— | 0.3−78.9%— | 1.6—— | |
| Cash from operating activities | −49—— | −30—— | −24—— | −38r−38—— | −29—— | −13—— | −15—— | −11—— | −9.1—— | −0.2r−30—— | |
| Capital expenditure | −0.0—— | — | −0.0—— | — | — | −0.0—— | −0.1—— | −0.0—— | — | −0.0—— | |
| Cash from investing activities | 6.1—— | −22—— | −0.0—— | — | — | −0.0−100%— | 5.0—— | −5.1−141%— | 13+19.2%— | 11—— | |
| Shares issued | — | — | — | — | — | — | — | — | 0.1—— | — | |
| Cash from financing activities | 52+6.2%— | 49+218%— | 15−20.9%— | 19r19−47.2%— | 37+12.0%— | 33+88.6%— | 17−12.3%— | 20+887%— | 2.0+1234%— | 0.2r−0.0—— | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | −0.0—— | — | |
| Change in cash | 8.2—— | −2.8—— | −9.2—— | −18−355%— | 7.2−62.6%— | 19+168%— | 7.1+78.3%— | 4.0−27.6%— | 5.5—— | −0.1r−19—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | — | — | — | — | — | 5.3−30.1%— | 6.7+31.2%— | 7.1+154%— | 7.3*+245%— | 7.6—— | 5.1—— | 2.8—— | 2.1*—— | |
| General and administrative | — | — | — | — | — | 9.4+93.0%— | 5.9+76.5%— | 5.8+82.1%— | 4.9*+115%— | 4.9—— | 3.3—— | 3.2—— | 2.3*—— | |
| Total costs and expenses | 64+22.5%— | 21+39.8%— | 18+46.4%— | 10−18.9%— | 15*+20.8%— | 15+17.9%— | 13+49.0%— | 13+116%— | 12*+178%— | 12—— | 8.4—— | 6.0—— | 4.4*—— | |
| Interest and finance income | 4.0+157%— | 1.8+223%— | 1.5+669%— | 0.3−7.8%— | 0.4*−11.4%— | 0.6−17.7%— | 0.2−77.0%— | 0.3−12.5%— | 0.5*+132%— | 0.7—— | 0.8—— | 0.4—— | 0.2*—— | |
| Interest expense and finance costs | 1.1+38.6%— | 0.3+34.4%— | 0.3+45.0%— | 0.3+48.1%— | 0.3*+27.4%— | 0.2−47.5%— | 0.2−76.2%— | 0.2−77.2%— | 0.2*−75.0%— | 0.4—— | 0.8—— | 0.8—— | 0.8*—— | |
| Other non-operating income (expense) | −48—— | 8.4+3257%— | −56—— | 0.3+340%— | 0.1*—— | 0.3—— | −0.2—— | 0.1—— | −0.2*—— | −0.0—— | −0.0—— | −0.5—— | −1.1*—— | |
| Net income including minority interests | −112—— | −12*—— | −75*—— | −10—— | −15*—— | −14*—— | −13*—— | −13—— | −12*—— | −13*—— | −8.5*—— | −6.5—— | −5.5*—— | |
| Net income attributable to shareholders | −112—— | −12—— | −75—— | −10—— | −15*—— | −14—— | −13—— | −13—— | −12*—— | −13—— | −8.5—— | −6.5—— | −5.5*—— | |
| Earnings per share, basic | — | -0.11—— | -0.80—— | -0.19—— | — | -0.28—— | -0.37—— | -0.37—— | — | -0.36—— | -0.25—— | -0.26—— | — | |
| Earnings per share, diluted | — | -0.11—— | -0.80—— | -0.19—— | — | -0.28—— | -0.37—— | -0.37—— | — | -0.36—— | -0.25—— | -0.26—— | — | |
| Shares, weighted average (basic) | 105+107%— | 105+107%— | 94+170%— | 53+53.9%— | — | 51+48.5%— | 35+1.1%— | 35+38.5%— | — | 34—— | 34—— | 25—— | — | |
| Shares, weighted average (diluted) | 105+107%— | 105+107%— | 94+170%— | 53+53.9%— | — | 51+48.5%— | 35+1.1%— | 35+38.5%— | — | 34—— | 34—— | 25—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 60—28.9% | 60+87.1%28.9% | 48−7.5%25.2% | 28+116%84.8% | 21+64.1%50.1% | 32+235%61.4% | 52+252%88.0% | 13−80.4%47.6% | 13−18.0%33.0% | 9.5—19.9% | 15—22.8% | 66—94.8% | 16—80.3% | |
| Short-term investments | 142—68.7% | 142+776%68.7% | 139+3855%73.2% | 1.2−88.4%3.6% | 15−28.4%37.0% | 16−51.5%31.1% | 3.5−92.4%6.0% | 10—37.4% | 22—55.9% | 33—69.6% | 47—71.9% | — | — | |
| Other current assets | — | — | — | — | — | 1.9−25.9%3.7% | 1.5+24.9%2.6% | 1.8+33.9%6.4% | 2.1+59.0%5.5% | 2.6—5.5% | 1.2—1.9% | 1.3—1.9% | 1.3—6.8% | |
| Current assets | 203—98.5% | 203+306%98.5% | 188+231%98.9% | 31+24.2%93.8% | 40+9.4%95.5% | 50+9.9%96.2% | 57−9.0%96.6% | 25−63.1%91.4% | 36+115%94.4% | 46—95.0% | 63—96.5% | 68—96.7% | 17—87.7% | |
| Property, plant and equipment | — | — | — | — | 0.0−62.5%0.0% | — | — | — | 0.0−38.5%0.0% | — | — | — | 0.0—0.1% | |
| Right-of-use (leased) assets | 1.0—0.5% | 1.0+1133%0.5% | 0.0−63.4%0.0% | 0.0−53.8%0.1% | 0.1−46.2%0.2% | 0.1+295%0.2% | 0.1+166%0.2% | 0.1+108%0.4% | 0.1+80.3%0.3% | 0.0—0.0% | 0.0—0.1% | 0.1—0.1% | 0.1—0.3% | |
| Goodwill | 1.0—0.5% | 1.00.0%0.5% | 1.00.0%0.5% | 1.00.0%3.1% | 1.00.0%2.5% | 1.00.0%2.0% | 1.00.0%1.8% | 1.00.0%3.8% | 1.00.0%2.7% | 1.0—2.2% | 1.0—1.6% | 1.0—1.5% | 1.0—5.3% | |
| Other intangible assets | 0.6—0.3% | 0.6−27.6%0.3% | 0.6−25.8%0.3% | 0.7−24.2%2.1% | 0.8−22.9%1.8% | 0.8−21.7%1.6% | 0.9−20.5%1.5% | 0.9−19.5%3.4% | 1.0−18.6%2.5% | 1.0—2.1% | 1.1—1.7% | 1.1—1.6% | 1.2—6.2% | |
| Total assets | 206—100% | 206+297%100% | 190+223%100% | 33+21.0%100% | 42+8.2%100% | 52+8.6%100% | 59−9.0%100% | 27−60.9%100% | 39+99.4%100% | 48—100% | 65—100% | 70—100% | 19—100% | |
| Accounts payable | — | — | — | — | — | 1.9+92.2%3.7% | 1.2+121%2.1% | 1.7+344%6.1% | 2.0+216%5.0% | 1.0—2.1% | 0.6—0.8% | 0.4—0.5% | 0.6—3.2% | |
| Current liabilities | 19—9.4% | 19+99.2%9.4% | 198+2206%104% | 12+66.0%35.7% | 9.1+35.9%21.7% | 9.7+44.9%18.7% | 8.6−37.4%14.5% | 7.1−65.3%26.1% | 6.7−67.9%17.3% | 6.7—14.0% | 14—21.1% | 21—29.4% | 21—107% | |
| Lease liabilities (non-current) | 0.7—0.3% | 0.7+3290%0.3% | — | — | 0.0−92.4%0.0% | 0.0—0.0% | 0.0—0.1% | 0.1—0.2% | 0.1+1000%0.2% | — | — | — | 0.0—0.0% | |
| Total liabilities | 26—12.4% | 26+39.5%12.4% | 205+1088%108% | 22+31.3%67.7% | 20+14.3%48.5% | 18+11.4%35.4% | 17−23.3%29.3% | 17−17.0%62.4% | 18−14.8%45.9% | 17—34.5% | 23—34.7% | 21—29.4% | 21—107% | |
| Retained earnings | −357—−173% | −357—−173% | −345—−181% | −270—−817% | −260—−623% | −246—−472% | −231—−392% | −218—−798% | −206—−532% | −193—−403% | −181—−279% | −172—−246% | −166—−856% | |
| Shareholders' equity | 181—87.6% | 181+438%87.6% | −15−135%−7.7% | 11+3.9%32.3% | 22+3.0%51.5% | 34+7.1%64.6% | 42−1.5%70.7% | 10−79.2%37.6% | 21—54.1% | 31—65.5% | 42—65.3% | 49—70.6% | −1.4—−7.5% | |
| Total liabilities and equity | 206—100% | 206+297%100% | 190+223%100% | 33+21.0%100% | 42+8.2%100% | 52+8.6%100% | 59−9.0%100% | 27−60.9%100% | 39+99.4%100% | 48—100% | 65—100% | 70—100% | 19—100% | |
| Shares outstanding | 110—— | 110+108%— | 103+107%— | 53+53.5%— | 53+53.5%— | 53+53.6%— | 50+44.7%— | 35+1.3%— | 35+63.9%— | 34—— | 34—— | 34—— | 21—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.2+2.6%— | 0.1*+16.7%— | 0.1*+5.5%— | 0.1−8.1%— | 0.1*−1.7%— | 0.1*−5.3%— | 0.1*−3.5%— | 0.1+8.8%— | 0.1*+1.8%— | 0.1*—— | 0.1*—— | 0.1—— | 0.1*—— | |
| Share-based compensation | 15+75.5%— | 7.7+229%— | 7.0+141%— | −0.7−131%— | 1.3*+4.7%— | 2.3+74.6%— | 2.9+98.6%— | 2.2+73.3%— | 1.2*—— | 1.3—— | 1.5—— | 1.3—— | — | |
| Cash from operating activities | −44—— | −8.4*—— | −11*—— | −6.9—— | −18*—— | −11*—— | −9.1*—— | −11—— | −9.2*—— | −10*—— | −4.9*—— | −5.3—— | −4.4*—— | |
| Capital expenditure | — | −0.0*—— | — | — | — | — | — | — | — | — | — | — | −0.0*—— | |
| Intangible assets bought | — | 0*—— | — | — | — | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −124−827%— | −1.7*—— | −138*−2156%— | 14+25.7%— | 0.7*−93.9%— | −13*−195%— | 6.7*—— | 11—— | 12*—— | 13*—— | — | — | −0.0*—— | |
| Cash from financing activities | 196—— | 22*+434%— | 168*—— | 0.0—— | 6.3*+818%— | 4.0*—— | — | — | 0.7*—— | −8.1*—— | −0.2*—— | 56—— | 0*—— | |
| Change in cash | 28+24.2%— | 12*—— | 20*−48.8%— | 7.4+2700%— | −11*−443%— | −20*—— | 39*—— | 0.3−99.5%— | 3.2*—— | −5.2*—— | −52*—— | 51—— | −4.4*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Achieve Life Sciences, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Richard Stewart | $1.4 M | $1.5 M | $964 K | $203 |
| 2024Andrew D. Goldberg | $2.5 M | $2.2 M | $1.1 M | $144 |
| 2023John Bencich | $1.7 M | $1.6 M | $1.3 M | $168 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Achieve Life Sciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 9 · Material agreement 4 · New debt 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2009 | $10 M | No. 1 | $10 to $50 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 | · | 11 | · | · | · | · | · | · | · | 16 | · | · | 27 |
| 2008 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2007 | · | · | · | · | · | · | · | · | · | · | 16 | · | 16 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 16 people (55% of workforce) | Restructuring planSEC 8-K | “As part of this restructuring, the Company will eliminate 16 positions, representing approximately 55% of the Company’s workforce.” | Filing | |
| 11 people (27% of workforce) | Restructuring planSEC 8-K | “(the “Company”) committed to a plan to reduce operating expenses, which included a workforce reduction of 11 employees, representing approximately 27% of the Company’s employees pr…” | Filing | |
| 49% of workforce | Restructuring planSEC 8-K | “The Company will reduce workforce by approximately 49%.” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 16 people | Restructuring planSEC 8-K | “(the “Company”) implemented a reduction in workforce (the “Reduction in Workforce”) pursuant to which the Company’s workforce was reduced by 16 positions, or approximately 25%, lea…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Achieve Life Sciences, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 10 November 2026automatic update · Nov 10, 2026
Achieve Life Sciences, Inc. announced results on 10 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $12 million.
- Mutual funds: 62 funds hold $98 millionautomatic update · Jul 31, 2026
62 mutual funds in 1 country hold shares of Achieve Life Sciences, Inc. worth $98 million, about 13.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 54 funds added shares and 5 sold; on balance they bought $65 million. Share splits are not counted as trading.
How Achieve Life Sciences, Inc. compares in Biotechnology
- Market cap$791 M · higher than 64% of 726
- Price / book36.8× · lower than 5% of 534
- FCF yield-6.3% · higher than 67% of 449
- 🇺🇸 Sana Biotechnology, Inc.$788 M
- 🇨🇳 HitGen Inc.$803 M
- 🇨🇳 Alphamab Oncology$767 M
- 🇺🇸 Gyre Therapeutics, Inc.$818 M
- 🇨🇳 Shanghai Hile Bio-Technology Co., Ltd.$818 M
- 🇺🇸 Ardelyx, Inc.$822 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Achieve Life Sciences, Inc.🇺🇸 | $791 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Sana Biotechnology, Inc.$788 M
- HitGen Inc.$803 M
- Alphamab Oncology$767 M
- Gyre Therapeutics, Inc.$818 M
- Shanghai Hile Bio-Technology Co., Ltd.$818 M
- Ardelyx, Inc.$822 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Achieve Life Sciences, Inc.? Verify and update this profile — free
Show Achieve Life Sciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.